AQST Nov 2024 4.000 call
| Previous close | 0.5000 |
| Open | 0.3800 |
| Bid | 0.0500 |
| Ask | 0.7500 |
| Strike | 4.00 |
| Expiry date | 2024-11-15 |
| Day's range | 0.3500 - 0.3800 |
| Contract range | N/A |
| Volume | |
| Open interest | 283 |
GlobeNewswireAquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
Sherry Korczynski joins the leadership team as Senior Vice President, Sales and MarketingDr. Stephen Wargacki promoted to Chief Science OfficerCassie Jung named Chief Operating Officer WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its l
- GlobeNewswire
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference
WARREN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two encore poster presentations highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm™ (epinephrine) sublingual film will be presented
Zacks5 Small Drug Stocks to Buy From a Recovering Industry
Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
